La catena delle opzioni mostra i dati chiave delle opzioni azionarie di EXSCIENTIA PLC ADS a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per EXSCIENTIA PLC ADS..

EXSCIENTIA PLC ADS (NASDAQ:EXAI) Azioni, Catena delle Opzioni

Exscientia

EXSCIENTIA PLC ADS

Exail Technologies SA

Recursion, Exscientia seek support for merger ahead of special meeting

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Exscientia Plc (EXAI – Research Report) today and set a price target of $5.70. Th...

Morgan Stanley Reaffirms Their Hold Rating on Exscientia Plc (EXAI)

Exscientia to receive $15M in milestones for Sanofi collaboration

Morgan Stanley Sticks to Its Hold Rating for Exscientia Plc (EXAI)

Exscientia Plc (EXAI) has released an update. Exscientia Plc has announced a key amendment to its transaction agreement with Recursion Pharmaceutic...

Exscientia Plc Enhances Board Collaboration with Recursion

Recursion (RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Re...

Recursion, Exscientia shareholders approve proposed combination

Exscientia Plc (EXAI) has released an update. Shareholders of Recursion and Exscientia have overwhelmingly approved a merger, expected to be finali...

Recursion and Exscientia Merger Approved by Shareholders

In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exscientia Plc (EXAI – Research Report), with a price target of ...

Barclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)

Exscientia Plc (EXAI) has released an update. Exscientia Plc merges with Recursion to form a powerful AI-driven drug discovery platform, marking a ...

Exscientia and Recursion Merge to Revolutionize Drug Discovery

Absci Corporation: Struggling To Live Up To Its AI Promise

ABSI

EXAI

NVDA

RLAY

RXRX

Press Releases

General

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

Exscientia Business Update for Second Quarter and First Half 2024

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Opinion

AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

News

Health Care

Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Comments

EXSCIENTIA PLC ADS

EXSCIENTIA PLC ADS (EXAI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO